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Background: Hepatocellular carcinoma (HCC) is a heterogeneous disease with high mortality rate. Recent genomic
studies have identified TP53, AXIN1, and CTNNB1 as the most frequently mutated genes. Lower frequency mutations
have been reported in ARID1A, ARID2 and JAK1. In addition, hepatitis B virus (HBV) integrations into the human
genome have been associated with HCC.
Results: Here, we deep-sequence 42 HCC patients with a combination of whole genome, exome and transcriptome
sequencing to identify the mutational landscape of HCC using a reasonably large discovery cohort. We find
frequent mutations in TP53, CTNNB1 and AXIN1, and rare but likely functional mutations in BAP1 and IDH1. Besides
frequent hepatitis B virus integrations at TERT, we identify translocations at the boundaries of TERT. A novel deletion
is identified in CTNNB1 in a region that is heavily mutated in multiple cancers. We also find multiple high-allelic
frequency mutations in the extracellular matrix protein LAMA2. Lower expression levels of LAMA2 correlate with a
proliferative signature, and predict poor survival and higher chance of cancer recurrence in HCC patients, suggesting
an important role of the extracellular matrix and cell adhesion in tumor progression of a subgroup of HCC patients.
Conclusions: The heterogeneous disease of HCC features diverse modes of genomic alteration. In addition to
common point mutations, structural variations and methylation changes, there are several virus-associated changes,
including gene disruption or activation, formation of chimeric viral-human transcripts, and DNA copy number changes.
Such a multitude of genomic events likely contributes to the heterogeneous nature of HCC.Background
Hepatocellular carcinoma (HCC) is the third leading cause
of cancer-related death, with a poor 5-year survival rate of
less than 10% [1]. While more than 600,000 new cases are
diagnosed annually, there is no effective targeted therapy.
HCC is highly heterogeneous and associated with various
etiological factors, including hepatitis B virus (HBV) or
hepatitis C virus (HCV) infection, alcohol consumption
and exposure to aflatoxin and possibly vinyl chloride [2].
Several emerging themes were revealed by recent genomic
studies [3-6], including recurrent mutations in TP53,
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article, unless otherwise stated.chromatin regulators like ARID1A and ARID2, as well
as HBV integration near TERT, CCNE1 and MLL4. The
frequently altered genes discovered by these studies
have differed, however, possibly due to small discovery
panels (up to 25 patients) and the inherent heterogen-
eity of HCC due to several associated etiological factors.
For example, activating mutations in CTNNB1 are mu-
tually exclusive with HBV infection [6] and hence would
not be prominent in a cohort enriched for HBV-infected
patients. Therefore, it might not be surprising that dif-
ferent studies have identified different genes that are
mutated in the population at low frequency, like ARID2,
ARID1A and JAK1. Another difficulty in constructing
the complete mutational landscape in HCC is the focused
nature of most previous studies, since it is not common for
a single study to comprehensively examine multiple types
of genomic changes that include point mutations, deletions,entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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have previously shown that HBV DNA frequently inte-
grates into the human genome, causing diverse changes
such as DNA copy number variation, chimeric viral-human
transcript fusions, and transcriptional activation [3]. Given
the disruptive nature of HBV integration, it is pertinent to
study all modes of genomic changes in the same context.
In this study, we analyzed a panel of 42 HCC patients
with a combination of whole-genome, exome and tran-
scriptome sequencing. We identified multiple high-allelic
frequency mutations in LAMA2. LAMA2 encodes the α
subunit of laminin, the major component of basal laminae.
Besides being a structural component of the extracellular
matrix, basal laminae can influence cell proliferation and
differentiation. Defective anchoring to laminins is wide-
spread in cancer [7]. The high incidence of mutations in
an extracellular matrix component like LAMA2 adds a
new dimension of underlying genetic components to this
rather complex disease. We also found two patients with
mutations in IDH1 at the R132 hotspot found in other
cancers [8,9], and one patient with truncated IDH2. The
tumor suppressor BAP1 was mutated in two patients. We
previously showed that HBV randomly integrates into the
human genome and results in several genomic and genetic
alterations [3]. Here we report HBV integrations in eight
HBV-infected patients, including integration in the vicin-
ity of three previously reported genes, TERT, CCNE1 and
MLL4. Aside from individual genes mutated in HCC, we
also examine the diverse modes of genomic alteration in
this heterogeneous disease, delineating both conventional
mutations and virus-associated changes that contribute to
liver oncogenesis.
Results
The mutational landscape of hepatocellular carcinoma
We analyzed 42 HCC tumor-normal pairs to identify fre-
quent and high-allelic frequency mutations. We sequenced
whole genomes and transcriptomes of 12 patients, and
exomes of 30 additional patients. We identified 49 non-
silent mutations per patient (median value; Table S1 in
Additional file 1; Figure S1A in Additional file 2) from the
12 whole genomes, and 54 non-silent somatic mutations
per patient (median value; Table S2 in Additional file 1;
Figure S2 in Additional file 2) from the 30 exomes. One of
the patients had an unusually high mutation rate (Figure S2
in Additional file 2), with >99% of the point mutations
of the C > T type (Table S2 in Additional file 1). The
mechanism of such a high mutation rate in this particu-
lar patient is not clear, but such a C > T mutation pattern
is consistent with APOBEC3B-mediated mutagenesis ob-
served in other types of cancers [10,11].
We found frequent non-silent mutations in TP53,
CTNNB1, AXIN1, LAMA2, ZFPM2 and TAF1L (Figure 1A).
We focused on mutations identified at high allelic frequencies(Figure 1B), as they are likely to be functional. Frequent
mutations in TP53, CTNNB1 and AXIN1 have been re-
ported previously in HCC, and these occur in 13 out of 42
patients (Figure 1A). Additionally, we found mutations in
IDH1 at codon 132 (2/42 cases; Figure 2A), a hotspot for
mutations in glioblastoma and intrahepatic cholangiocar-
cinoma [9], thus expanding the indications for IDH1 mu-
tations. Mutations at codon 132 in IDH1 have been shown
to dominantly inhibit the catalytic activity of IDH1, which
normally functions to catalyze the oxidative decarboxyl-
ation of isocitrate to α-ketoglutarate, and contribute to
tumorigenesis by inducing the HIF-1 pathway [12]. Inter-
estingly, another patient carried a nonsense mutation in
IDH2, which is also frequently mutated in cancer and has
a similar effect to IDH1. A third IDH family member,
IDH3A, which encodes the alpha-subunit of IDH3, carried
a non-synonymous mutation (Table S2 in Additional file 1),
although its significance is not clear. Further, we found
mutations in the tumor suppressor BAP1 [13] in two pa-
tients (Figure 2B). BAP1 is a deubiquitylase associated
with protein complexes regulating key cellular pathways,
including the cell cycle, cellular differentiation, cell death,
gluconeogenesis and the DNA damage response [14]. One
patient carried a deletion leading to a frame-shift, along
with another non-synonymous mutation. The second pa-
tient had a D184V mutation, a position important for
catalytic activity, based on sequence similarity to the resi-
due D176 from UCHL1 [15]. While frequent somatic
BAP1 mutations have been found in mesothelioma, uveal
melanoma and cutaneous melanoma response [14], we re-
port the first finding of BAP1 mutation in HCC. Another
notable mutation was a E545K mutation in PIK3CA
(Table S2 in Additional file 1), which is a hotspot mutation
in the helical domain leading to constitutive activa-
tion [16,17]. Several other mutations previously re-
ported in cancer were found as singleton cases (Table S2
in Additional file 1).
Aberrations in the members of the Wnt signaling path-
way are reported to be frequent in HCC [6]. Besides point
mutations in CTNNB1 and AXIN1, we also found partial
deletions in these genes. The CTNNB1 deletion spans
exons 3 and 4 (Figure S3A,B in Additional file 2; Table S5
in Additional file 1). This in-frame deletion removes the
amino terminus of β-catenin, a region heavily mutated
in multiple cancers (Figure 2C). Since the amino terminus
is involved in degradation of β-catenin, the deletion likely
results in its stabilization. We previously reported an
AXIN1 deletion [3] that comprises the last three exons of
the gene and results in a fusion with LUC7L (Table S6 in
Additional file 1), likely leading to functional loss.
Hepatitis B virus integration into the human genome
HBV integration is another mechanism for influencing
gene expression and function in HCC. HBV can randomly
Figure 1 Summary of genomic aberrations in hepatocellular carcinoma. (A) Select genes that have multiple point mutations at high allelic
frequency or structural variations are shown. Select cancer gene census genes that showed mutations at high allelic frequency and highly clonal
viral integrations are also shown. HBV infection status was known for the 12 whole-genome sequencing samples. For these samples, HBV infection
status is shown as a plus sign if infected, and a minus sign if no infection was detected. (B) Allelic frequency profiles of frequently mutated genes
across whole genomes and exomes. For each mutant allele found in the study, the percentile of its allelic frequency (calculated for each sample
separately) is shown on the y-axis. The red bars indicate the median value of the percentile allelic frequency. Blue dots represent chosen
mutations, where the median percentile value was more than 0.5, while the grey dots show examples of genes that had median values below
0.5 and were rejected.
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[3,4,18,19]. Recurrent HBV integrations near cancer-
related genes like TERT [4] indicate that HBV can play a
causal role in HCC. From the whole genomes of HBV-
infected patients we identified 146 HBV integration sites(Table S3 in Additional file 1), and from their transcrip-
tomes we identified 545 chimeric transcripts (Table S4
in Additional file 1). The number of integration sites per
patient ranged from 2 to 28 sites in the tumor samples
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Figure 2 Mutations in IDH1, BAP1 and CTNNB1. (A) IDH1 is mutated in two patients at the hotspot R132. (B) BAP1 mutation in two patients.
Patient 3885 has a D184V mutation, a site that is important for the peptidase enzymatic activity (by homology). The other patient (9113) carries
two mutations, including a point mutation, R237C, and a frameshift deletion at position 354. (C) An in-frame deletion in CTNNB1 in patient 30147.
The deletion spans 121 amino acids near the amino-terminal. This region is involved in the degradation of β-catenin and is frequently mutated in
cancer, as shown by clustering of mutations in this region in the COSMIC database. Each green box is a mutation instance in COSMIC. Overlapping,
unique mutations have been stacked.
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to tumors (Figure 3A), as the tumors showed high
amounts of human-viral chimeric DNA compared withthe tumor-adjacent samples. We found integrations
near three known recurrent integration targets [4]: two






























































Figure 3 (See legend on next page.)
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Figure 3 Hepatitis B virus integration and chimeric transcription in hepatocellular carcinoma. (A) Viral integrations in 12 whole-genome
sequenced samples were determined based on human-viral chimeric reads. Overlapping or nearby (within 500 bp) chimeric reads were clustered
together, and the closest gene to the human-viral junction of each cluster was determined. In the plot, each point represents a chimeric read
cluster, and the y-axis represents the total number of chimeric reads per cluster per gigabase of mapped human bases for that sample. The
human junction is shown on the x-axis. For each sample, the cluster with the highest number of chimeric reads is labeled with the closest gene.
(B) Two hotspots for viral breakpoints in viral-human chimeric transcripts. Human-viral chimeric RNA reads were clustered based on close vicinity
(up to 500 bp). The scatter plot shows the mapping of the clusters on the viral genome (y-axis) versus the linearized human genome (x-axis). The
size of the points is proportional to the number of reads belonging to the cluster. The histogram on the y-axis represents the frequency of
chimera observed along the viral genome. Two hotspots are observable. The most frequent viral junction is the region at the 3’ end of the
X gene. A second, less frequent hotspot is seen at the S gene. (C) Chimeric transcripts show enrichment for viral promoter origin and human
exon exclusion. Histograms representing chimeric RNA-Seq read counts are shown. Chimeric reads were classified as downstream, when the viral
positive strand was 3’ of the human sequence, or upstream, when the viral positive strand was 5’ of the human sequence (consistent with viral
promoter-driven transcription). They were further classified for inclusion or exclusion of human exon sequence. Specific enrichment of the
chimeric transcripts can be seen when the viral sequence is upstream of the breakpoint, and human exons are excluded.
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exon of MLL4 [3]. These integrations occur at high
clonal frequency (Table S3 in Additional file 1). The
HBV integration near CCNE1 correlated with extensive
genomic instability at this region, featuring at least
three inversions and one inter-chromosomal transloca-
tion to chromosome 7 (Figure S4 in Additional file 2).
Intriguingly, none of the breakpoints disrupted the
CCNE1 coding sequence. Other highly clonal integra-
tion sites were mapped near TNFSF4 and AGPAT6, in
addition to ANGPT1 and CASP12 as previously re-
ported [3].Hepatitis B virus-mediated transcription from viral
promoters
Besides HBV viral integration at the DNA level, we also
performed comprehensive analysis of available RNA-Seq
data to identify fusion transcripts between HBV and hu-
man sequences. A large number of such chimeric tran-
scripts were identified (Table S4 in Additional file 1).
Chimeric transcripts were preferentially fused to two
breakpoints in the viral genome: one near the 3’ end of
the X gene and the other within the S gene (Figure 3B;
Figure S5A,B in Additional file 2). Human-viral chimeric
transcripts may include the viral sequence upstream or
downstream of the breakpoint. The former, which is
consistent with transcription initiation from a viral pro-
moter, is enriched in the chimera (Figure 3C). If chimeric
transcription initiated from a human promoter, we would
expect to see enrichment for inclusion of human exons in
the chimera; however, that was not the case (Figure 3C).
The larger prominence of the breakpoint at the 3’ end of
the X gene was likely due to linearization (and consequent
integration) of the viral DNA at the DR1 site, which was
previously identified as a fusion hotspot for human-HBV
chimeric RNA [3,18]. Full length HBx has been shown
to have oncogenic potential [20]. Interestingly, truncation
of HBsAg can confer advantage over immune surveillance[21] and pre-S deletions are associated with development
of HCC [22].
Multiple modes of activation of TERT
The telomerase gene TERT is upregulated in multiple
cancers [23]. Here, we observed two modes of perturb-
ation of TERT: viral integrations into the promoter of
TERT in two patients (Figure 4, patients H166 and H219),
and translocations in two other patients (Figure 4, patients
30996 and 30374). In all four cases, the breakpoints did
not disrupt the exons and TERT was expressed in tumor
(Figure 4) but not in the matched normal tissue (data not
shown). In patient H219, chimeric reads showing fusion
between the 5’ UTR of TERT mRNA and viral sequence
were evident (Table S4 in Additional file 1), suggesting a
direct role of HBV in activating TERT expression. How-
ever, we note that there was bidirectional transcription at
this insertion, and transcription in the direction of the
TERT gene was the least prevalent of the two transcripts
resulting from the insertion. In patient H166, evidence for
fusion between viral sequence and a region upstream of
the TERT transcription start site was found, but no direct
evidence of a fusion between TERT mRNA and viral
mRNA was found. In patient 30996, TERT was translo-
cated to a region on chromosome 5 that in turn showed
extensive rearrangements in a chromothripsis-like fashion
(Figure S6 in Additional file 2). Lastly, in patient 30374,
the promoter region of TERT was involved in an inter-
chromosomal translocation to a region upstream of RXRA
on chromosome 9 (Table S5 in Additional file 1), likely
resulting in misregulation of TERT. TERT was not
expressed in the non-tumor samples in three out of
these four patients, while RNA-Seq data were not available
for the fourth patient (30996).
LAMA2 is frequently mutated in hepatocellular carcinoma
We found that approximately 14% of the samples analyzed
(6/42) had non-silent mutations in LAMA2 (Figure 1A;
Tables S1 and S2 in Additional file 1), a member of the
Figure 4 Multiple modes of TERT activation. Viral integration and structural variations at the TERT locus in tumor samples from four patients.
Patient 30996 has an intra-chromosomal inversion supported by 132 whole-genome sequencing reads (red dashed line). Patient 30374 has an
inter-chromosomal translocation to chromosome 9 supported by 27 reads (purple block). Viral integration junctions are shown as red triangles
and vertical grey lines (patients H166 and H219). RNASeq.T: RNA-Seq coverage in the tumor sample. Coverage is on a linear scale in patients
30996 and 30374, and on a log2 scale in patients H166 and H219. CNV: copy number ratio of the tumor sample relative to the non-tumor sample
(log2 scale).
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cies of these mutations suggest early occurrence during
tumor development (Figure 1B). Although the co-
occurrence of LAMA2 mutations and CTNNB1/AXIN1
mutations is low, the apparent exclusivity is not signifi-
cant (Fisher exact P-value = 0.3848). To understand the
prevalence of LAMA2 mutations, we examined data
from other studies, and found that approximately 6%
(5/88) of the samples in the Asia Cancer Research
Group study [4], and approximately 5% (5/104) of the
samples in the Riken liver cancer cohort from the Inter-
national Cancer Genome Consortium also had LAMA2
mutations. The mutation prevalence will likely vary be-
tween different patient cohorts, partly due to extensive
heterogeneity observed in HCC. We also found that
LAMA2 is frequently mutated in other cancers, includ-
ing lung adenocarcinoma (11%), lung squamous cell car-
cinoma (13%), uterine corpus endometrioid carcinoma
(13%), and head and neck squamous cell carcinoma
(10%) (data source: The Cancer Genome Atlas).The non-focal nature of LAMA2 mutations in liver
cancer (Figure S7 in Additional file 2) suggests it plays a
tumor suppressor role. Accordingly, downregulation of
LAMA2 expression was connected to tumor progression
in other tumor types like laryngeal squamous cell carcin-
oma [24] and breast cancer [25]. We examined a compre-
hensive panel of tumor tissues for expression profiling,
and found downregulation of LAMA2 across multiple
cancer types, most notably in ovarian, lung and colorectal
cancer (Figure 5A). In addition, we examined multiple
cancer cell lines and found that a decrease in LAMA2 ex-
pression was accompanied by an increase in DNA methy-
lation near the transcription start site (Figures S8 and S9
in Additional file 2). Furthermore, we observed significant
downregulation of LAMA2 expression in a large cohort
of un-treated HCC patients with clinical data from the
University of Hong Kong [26] (Figure 5B). Promoter
DNA methylation, downregulation across multiple can-
cer types, and mutations in a number of cancer indica-
tions support a tumor suppressor role for this gene.
Figure 5 LAMA2 status is associated with clinical outcome in hepatocellular carcinoma. (A) Microarray-based expression profile of LAMA2
across a panel of cancer and normal human tissues (Gene Logic, Gaithersburg, MD, USA). Numbers at the top are -log10 P-values for a two-sided
t-test comparing the expression values between the normal (green) and cancer (red) samples of the same tissue. (B) Microarray-based expression
profile of LAMA2 in 300 HCC patients from University of Hong Kong (data from Gene Expression Omnibus series GSE25097). The number at the
top is the -log10 P-value for a two-sided t-test comparing the expression values between the non-tumor (blue) and cancer (red) samples. (C)
Kaplan-Meier curves for survival of LAMA2-low versus LAMA2-high HCC patients from a cohort of 228 HCC patients from the University of Hong
Kong. Patients with low LAMA2 expression show poorer overall survival (left panel) and disease-free survival (right panel) by log-rank test (P-values
of 0.024 and 0.026, respectively). HR: hazard ratio between LAMA-high and LAMA-low samples.
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clinical outcome of HCC patients, we examined the pa-
tient survival data from the University of Hong Kong
cohort of HCC patients (228 HCC samples with survival
data). We found that patients with lower LAMA2 ex-
pression level showed significantly worse survival out-
come (Figure 5C; P-value = 0.024, log-rank test). The
effect size was greater upon stratifying the patients into
upper and lower quartiles instead of median-based
stratification (Figure S10 in Additional file 2). Among the
5 LAMA family members, only LAMA2 showed a signifi-
cant relation with clinical outcome. Moreover, patients
with low LAMA2 expression were 30% more likely to have
tumor recurrence (odds ratio = 1.7, P = 0.034, Chi-Squaretest). Thus, LAMA2 low expressing tumors appear to rep-
resent a more aggressive subtype of HCC. Interestingly,
compared with tumors with wild-type LAMA2, tumors
with LAMA2 mutations showed histopathological features
of poorly differentiated tumors, with substantial cellular
and nuclear atypia and moderate to abundant stroma inter-
spersed between cells (Figure 6). To understand the under-
lying molecular mechanism of such differences in clinical
outcome, we compared the LAMA2-low with the LAMA2-
high tumors and found striking enrichment for upregula-
tion of cell cycle genes (Figure S11 in Additional file 2).
A similar trend was also observed in breast, colorectal
and lung cancers (Figure S11 in Additional file 2). There-
fore, the LAMA2-deficient samples represent a subgroup
Figure 6 Morphology of hepatocellular carcinomas with LAMA2 mutations. Hematoxylin and eosin (H&E)-stained sections of HCC with
LAMA2 mutation (upper panels, 9193, 3206A7 009) show poorly differentiated neoplastic hepatocytes with cellular and nuclear pleomorphism,
mitotic figures (arrow) and moderate to abundant stroma (asterisks). H&E-stained sections of HCC with wild-type LAMA2 generally have more
uniform, well-differentiated neoplastic cell morphology (lower panels). Scale bar is 20 μm.
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omas, and LAMA2-based stratification appears to apply to
other cancer types as well.
Discussion
Multiple efforts using deep sequencing of HCC are now
revealing important players in this heterogeneous dis-
ease. Previous genomic studies have implicated the role
of tumor suppressor TP53, Wnt-signaling components
CTNNB1 and AXIN1, telomerase TERT, cell cycle regula-
tor CCNE1, and chromatin regulators like MLL4, ARID1A
and ARID2, although different studies have identified
different subsets of these players. Here we report low
frequency mutations in tumor suppressor BAP1 and
metabolic genes IDH1 and IDH2 in HCC. Although mu-
tations in these genes have been reported in other can-
cer types such as glioblastoma and mesothelioma [8,14],
BAP1, IDH1 and IDH2 have not been previously linked
to HCC. Since mutant IDH1 has been pursued as an anti-
cancer target in glioma [27], it is conceivable that HCC
patients carrying the R132 mutation can also benefit from
such IDH1 inhibitors. Similarly, HCC patients with
PIK3CA E545K mutation can benefit from inhibitors
effective against the kinase activity of this mutant [28].
It is conceivable that other PIK3CA mutations may
also be present in HCC.
Interestingly, we observed frequent mutations in the
extracellular matrix gene LAMA2 in liver cancer pa-
tients. Specific upregulation of LAMA2 expression in
cirrhotic hepatocytes (Figure 5B) suggests that basal
laminae may be required for controlled regeneration fol-
lowing liver injury. Low expression of LAMA2 is tied topoor survival outcome, high recurrence of HCC, and up-
regulation of cell cycle genes. We compared the LAMA2
expression profile, using the transcriptome data from 12
tumors, with those of poor-prognosis stemness markers
like EPCAM, PROM1 (CD133), THY1 (CD90), NCAM
and KRT9 (CK19), but did not find any conclusive evi-
dence of correlation with these markers, although there
was a weak correlation with CD90 (Pearson correlation
coefficient = 0.65). It is conceivable that functional LAMA2
in the extracellular matrix may keep the proliferation of
regenerating hepatocytes in check, and defective or lack of
LAMA2 facilitates tumor progression. This is also sup-
ported by the fact that the loss of cell surface anchoring to
basal laminae has been found to promote tumor growth
and cell proliferation [7]. Moreover, soluble laminin in cul-
ture can suppress cell proliferation in mammary epithelial
cells [29]. DNA methylation at the LAMA2 promoter re-
gion found by us and others [30] suggests that epigenetic
mechanisms may target LAMA2 in multiple cancers.
These findings suggest the importance of the extracellular
matrix during HCC development and perhaps other
types of cancers as well. This has potential implications
on stratification of HCC patients and on decisions about
therapeutic options for such categories of patients.
While the expression of LAMA2 seems to be related
to DNA methylation, the TERT gene appears to be influ-
enced by other modes of genomic alteration. In two of our
HCC samples, the HBV viral DNA is integrated into the
promoter of TERT, leading to the activation of TERT ex-
pression. In two other HCC patients, viral-independent
translocation was observed, juxtaposing the TERT pro-
moter on other active genomic regions. All four such
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compared with adjacent liver tissues based on our RNA-
Seq data (Figure 4). More recently, point mutations have
been found in the promoter region of TERT in multiple
types of cancer, leading to higher TERT mRNA expression
[31,32]. Clearly, TERT activation is common in human
cancers and is likely oncogenic, but the mechanism of
gene activation may differ between cancer types. While we
did not find any point mutations in the TERT promoter in
HCC, other HBV-dependent and HBV-independent gen-
omic events seem to be involved in alternative mecha-
nisms of TERT activation.
Overall, there is a constellation of genomic alterations
in HCC (Figure 7). Among conventional mutations, point
mutations are clearly the most studied type of changes in
HCC due to mature technologies for detecting such muta-
tions. Large coding region deletions, such as the CTNNB1
deletion we report here (Figure 2C), are usually under-
studied but their functional importance should not be ig-
nored. Perhaps the most notable genomic alterations in
the HBV-positive patients are various changes caused by
viral DNA integration into the human genome. Based on
our work and that of others [3–5], patterns of HBV-based
mutagenesis are starting to emerge. In some patients, inte-
grated HBV viral promoter would activate nearby genes
such as TERT and ANGPT1. In others, HBV integration
sites occur in the middle of human genes such as MLL4,
causing gene disruption and/or viral-human chimera tran-
scripts. HBV integration also leads to local genomic in-
stability, further causing DNA copy number changes [3].
Such diverse modes of genomic alteration add genetic
complexity to HCC (Figure 7), likely leading to its highly
heterogeneous nature. Deeper understanding of these
complex patterns of mutations could also provide better
understanding of the etiology of HCC and possibly lead toFigure 7 Diverse modes of genetic alterations in hepatocellular carcin
in other cancers, while the virus-associated changes are unique to HBV-infe
alteration are shown, compiled from multiple studies.development of novel anti-HCC therapeutics. For ex-
ample, the HBx-MLL4 chimera fusions potentially pro-
duce cancer-specific proteins that can be specifically
targeted therapeutically, and the TERT gene activation
modes may suggest different diagnostic markers for a
subset of HCC patients. With more comprehensive gen-
omic characterization of liver cancer patients, more de-
tailed and reproducible cancer subtypes will emerge
that can eventually guide clinical diagnostics and treat-
ment management.
Conclusion
We found diverse modes of genomic alteration in HCC
that affect important players in this disease. Point muta-
tions and structural variations affected both AXIN1 and
CTNNB1. We found HBV integrations in the TERT pro-
moter, and virus-independent TERT translocations, likely
leading to activation of TERT expression. HBV integra-
tions occurred in MLL4, CCNE1 and TERT, leading to in-
creased expression of CCNE1 and TERT, or HBx-MLL4
fusion. TP53, AXIN1 and CTNNB1 were the most fre-
quently mutated genes in our cohort. LAMA2 showed
high allelic frequency mutations, and we also found point
mutations in BAP1, IDH1, IDH2 and PIK3CA.
Materials and methods
Samples and sequencing
Frozen tissue and peripheral blood mononuclear cell
(PBMC) samples were obtained from commercial sources
(Seracare LifeSciences, Milford, MA, USA; ProteoGenex,
Culver City, CA, USA and Indivumed, Baltimore, MD,
USA). Appropriate informed consent and institutional re-
view board approval was obtained based on a representa-
tion and warranty from the vendors. Four-micron thick
frozen sections were obtained from both primary HCComa. Conventional mutations are the changes that can also be seen
cted HCC tumors. Examples of genes associated with each genetic
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pathological evaluation by standard hematoxylin and
eosin stain. Two distinct sets of samples were used for
whole-genome sequencing and exome-sequencing. For
whole-genome sequencing, tumor and tumor-adjacent
samples from 12 patients were sequenced at 78× to 132×
coverage using the Complete Genomics (Mountain View,
CA, USA) platform. Of these 12 patients, 4 were reported
previously [3]. Eight patients were confirmed to be HBV-
positive by PCR. Thirty sets of tumor and tumor-adjacent
samples were exome-sequenced using Illumina Hi-Seq.
Exome sequencing was performed at a median read count
of 79.9 million reads (range was 44.2 to 250 million).
Uniquely mapped reads (35 to 213 million; 67.5 million
median value) were used for variant calling.
Variant calling
High-throughput reads from whole-genome sequencing
were mapped by Complete Genomics to the human gen-
ome (NCBI build 37). The mean mate gap post-mapping
was approximately 311 bp. Single nucleotide variation,
short indels and substitutions, large-scale structural vari-
ation, and copy number variation data were provided by
Complete Genomics (standard pipeline version 2.0.1.6).
Somatic mutations were called using open-source cga-
tools v.1.5 [33]. Mutations with a somatic score greater
than -5 were retained. Further filtering of somatic muta-
tions was done by removing mutations that were com-
mon with dbSNP build 132, a set of 69 normal genomes
from Complete Genomics [34], the 1000 Genomes
Project, and 2,440 exomes from NHLBI [35]. Any mutations
that were also present in COSMIC v.62 were retained.
The resulting set of mutations constitutes high-confidence
mutations used in all the analyses in this study. For deter-
mining viral reads, whole-genome sequencing reads where
at least one arm was not mappable to the human genome
were mapped to a consensus HBV genome sequence using
mapping tools from Real Time Genomics® (Hamilton,
New Zealand).
Exome sequencing reads from the Illumina platform
were mapped to UCSC human genome (GRCh37/hg19)
using the default parameters of the BWA software [36].
Duplicate read removal and local realignment were per-
formed as described previously [37]. Variant calling was
performed on the tumor and normal BAM files using
the Strelka algorithm [38] with the BWA default config-
uration file and a minimum variant quality of 30. Known
germline variations represented in dbSNP build 131 [39]
or 6,515 previously published normal exomes [40], but
not represented in COSMIC v62 [41], were excluded. In
addition, predicted somatic variations were additionally
filtered to have a minimum variant allele frequency of
5% and not exceeding that number in the matched nor-
mal sample.Somatic mutation calls from the whole genomes and
exomes were pooled and the number of tumor samples
carrying a mutation was tallied for each gene. For genes
mutated in three or more samples, we selected those
that were preferentially mutated at high allele frequencies
across multiple patients. This eliminated some genes
that were apparently mutated in a large number of tu-
mors, but showed low allelic frequencies across these
tumors (Figure 1B). Among the genes that were mutated
in two samples, we focused on cancer gene census genes.
Among these cases, IDH1 was recurrently mutated at pos-
ition R132, and BAP1 carried three high allelic frequency
mutations, two of them in the same tumor. Other notable
mutations included a nonsense mutation in IDH2 at
amino acid 63, and a E545K mutation in PIK3CA, which
is a hotspot mutation in several cancers [16].
Mapping to the hepatitis B virus genome
Complete Genomics reads were mapped to the HBV
consensus genome using the Real Time Genomics® soft-
ware [42]. The subset of reads with minimum one mate
pair mapping to the HBV genome were mapped to a
‘hybrid genome’ - a combination of the human genome
(hg19) and the HBV virus genome. The hybrid genome
was created by merging the FASTA files of the human
genome (hg19) and the HBV consensus genome, so that
the viral genome is presented as an additional ‘pseudo’
chromosome of the human genome. Based on a Phred-
like quality score cutoff of minimum 20, aligned reads
were further filtered for reads with one mate pair map-
ping uniquely to the human genome and the other mate
pair mapping uniquely to the HBV genome.
Determination of viral integration sites and viral-human
fusion transcripts
For both whole-genome sequencing and transcriptome
sequencing, human-viral chimeric reads were grouped
into chimeric clusters. If a boundary of a read was within
500 bp of the boundary of another read on the human
as well as the viral arm, the two reads were assigned to
the same cluster. Each cluster represents a human-viral
junction, and two such junctions are expected per viral
insertion site in the human genome. However, two junc-
tions were not always detectable, likely due to lack of
coverage or difficulty in mapping at one of the junctions.
For whole-genome sequencing, we identified 146 such
clusters (Table S3 in Additional file 1), and 612 clusters
for RNA-Seq (Table S4 in Additional file 1), with at least
two reads per cluster. Since two nearby chimeric clusters
on the human genome may represent the same viral in-
tegration event, for the purpose of estimating the clonal-
ity of each integration (Figure 3A), we reduced this
redundancy by retaining only the cluster with the higher
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clusters are within 2 kb of each other on the human
genome.
Chimeric transcripts showed two hotspots for break-
points on the viral genome (Figure 3B). To examine
these in more detail, we classified the human-viral break-
points from whole genome and transcriptome data into
two types: one where the fused viral sequence is upstream
of the breakpoint in the viral genome, and the other where
the viral sequence is downstream of the breakpoint
(Figure 3C). The enrichment observed was especially strik-
ing for chimeric transcripts with upstream viral break-
points, indicating that viral promoters (for X and S genes)
are the likely driving factors for these fusion transcripts.LAMA2 expression in multiple tissues
Expression data were obtained from a panel of 37 tissues
from Gene Logic (Gaithersburg, MD, USA; Affymetrix
HG-U133 platform, representing 3,600 normal and 1,701
neoplastic samples from different human tissues). Tissues
that showed significant expression change in LAMA2
(P ≤ 0.001, two-sided t-test) are shown (Figure 5A). Ex-
pression was significantly decreased in breast, cervix, colo-
rectal, endometrium, kidney, lung, lymphoid, ovary, skin,
and thyroid tumor tissues.DNA methylation analysis
DNA methylation was measured using Illumina Infinium
450 K BeadChip and preprocessed using the Bioconductor
lumi package [43] with default settings (within-sample
quantile color bias adjustment plus across-sample quantile
normalization of pooled probe intensities). The methyla-
tion plot was produced using Bioconductor methyAnalysis
package.Relation between clinical data and LAMA2 expression
A cohort of 228 primary HCC samples from the Univer-
sity of Hong Kong was used for evaluating the effect of
LAMA2 expression on survival. Statistical analysis was
performed using IBM SPSS version 16.0 (Armonk, NY,
USA) for Windows. For clinical correlation analysis with
survival rates, continuous variables were modeled as cat-
egorical variables. Univariate analysis of LAMA2 expres-
sion on overall survival and disease-free survival rates was
performed using the Kaplan-Meier method. The subjects
were equally divided into high- and low-expression arms
using the median value as cutoff (Figure 5C). To achieve
more stringent stratification, upper and lower quartiles
were used instead of median-based separation. The result-
ing Kaplan-Meier plots show a higher level of separation
(Figure S10 in Additional file 2).Detection of structural variation and potential gene
fusion events
We utilized the paired-end nature of the sequencing
reads to detect structural variations (Table S5 in
Additional file 1) and potential gene fusion events (Table
S6 in Additional file 1). The method used to detect struc-
tural variation was as previously described [3]. We further
filtered somatic structural variants for matched or unre-
lated normal samples. For these putative somatic struc-
tural variants, we further searched for structural variation
events that potentially lead to fusion gene events by the
following criteria: 1) the somatic structural variant break-
points defined by DNA-Seq overlap with a pair of distinct
human genes (refGene); 2) the RNA-Seq data support
the fusion occurred between these two fusion partners.
For detecting fusion at the RNA level, we applied both
ChimeraScan [44] and gStruct (Thomas Wu, unpub-
lished). The somatic structural variants that lead to puta-
tive fusion events are reported in Table S5 in Additional
file 1.
Data availability
Sequence data have been deposited at the European
Genome-phenome Archive [45], which is hosted by the
EBI, under accession number EGAS00001000824.
ICGC mutation data were accessed from the ICGC
data portal [46]. The raw data from this study can be ob-
tained from the European Genome-phenome Archive,
study accession EGAS00001000678. Expression data for
LAMA2 from the university of Hong Kong are available
from the Gene Expression Omnibus repository, with acces-
sion GSE25097. LAMA2 mutation data from Asia Cancer
Research Group study can be accessed at [47]. The Cancer
Genome Atlas data were obtained from dbGaP (study
accession phs000178.v8.p7).
Additional files
Additional file 1: Table S1. High confidence mutations in 12 HCC
tumors from whole-genome sequencing. Table S2. High confidence
mutations in 30 HCC samples from exome sequencing. Table S3. Viral
integrations identified from whole-genome sequencing of eight HCC patients
carrying HBV infection. Table S4. Summary of human-viral chimeric RNA
reads identified from RNA sequencing of eight HCC patients carrying HBV
infection. Table S5. Somatic structural variation breakpoints identified
computationally from whole-genome sequencing of 12 HCC patients.
Table S6. Somatic fusion transcripts identified computationally from
RNA sequencing and whole genome sequencing of 12 HCC patients.
Additional file 2: Figure S1. Somatic mutation frequency and
mutation signature from whole genome sequencing of 12 HCC patients.
Figure S2. Exome-based somatic mutation frequency in 30 HCC patients.
Figure S3. CTNNB1 structural variant in patient 30147. Figure S4. Structural
variation and viral insertion near CCNE1. Figure S5. Frequencies of
human-viral chimeric reads based on whole genome and transcriptome.
Figure S6. Translocation of TERT in patient 30996. Figure S7. Non-silent
LAMA2 mutations. Figure S8. DNA methylation and expression of
LAMA2 in breast cancer cell lines. Figure S9. DNA methylation and
expression of LAMA2 in lung cancer cell lines. Figure S10. Survival analysis for
Jhunjhunwala et al. Genome Biology 2014, 15:436 Page 13 of 14
http://genomebiology.com/2014/15/8/436LAMA2-low and LAMA2-high patients. Figure S11. LAMA2 downregulation is
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